19.6 C
New York
Tuesday, August 16, 2022

Moderna, Inc. (MRNA) Stock Leaping Forward in Premarket, Here’s the Reason

 Moderna, Inc. (MRNA), a biotechnology company, has soared 5.07% in the premarket trading session. As a result, MRNA stock is trading at $309.74 at the time of the writing. The increase could be attributed to the company’s announcement of preliminary booster data to address the omicron variant. On Friday, MRNA closed the day at $294.80 after increasing 4.53% during regular trading hours.

Why MRNA Soaring?

On Monday, MRNA announced the preliminary neutralizing antibody data against the Omicron variant after the company’s booster candidates at 50 µg and 100 µg dose levels. Currently, the 50 µg booster of mRNA-1273 increased neutralizing antibody levels against Omicron approximately 37-fold against the pre boost level and a 100 µg dose of mRNA-1273 increased neutralizing antibody levels approximately 83-fold compared to pre-boost levels.


Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .

Sponsored


Q3 2021 Operational Results

On 4th November, MRNA released the operational results for the third quarter of the fiscal year 2021. The quarter ended on 30th September. The total revenue generated by the company during the period was $4.9 billion against $157 million for the same period of 2020. The total operating expenses bore by the company during the period were $1.4 billion against $392 million for the same period of 2020. The net income generated by the company during the quarter was $3.3 billion (or $8.27 and $7.70 per basic and diluted share) against the net loss of $233 million (or $0.59 per basic and diluted share) for the same quarter of 2020.

Executive Commentary

Stéphane Bancel, Chief Executive Officer of MRNA, while commenting on the results said that the company is humbled to have hundreds of millions of people around the world with its COVID 19 vaccine. Yet the company knows that its work is not done and the company would not rest until its vaccine is available to everyone who needs it. The company is more energized than ever by the impact its platform will have on human health.

Future Outlook for MRNA

During the last three months, MRNA stock has declined more than 30%. The decline could be associated with the uncertainty related to the clinical trials being carried out recently. Analysts believe that just like the impact the COVID shot had on the stock, the upcoming results of other clinical trials would also impart the influence on the stock in the upcoming months.

Latest news

Related news

LEAVE A REPLY

Please enter your comment!
Please enter your name here

2887

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

DOWNLOAD FREE EBOOK

BEST INFLATION STOCKS 2022

We put together a list of the best stocks that

we think can explode over the next 12 months.

2888

SPECIAL GIFT

2889
2890
2891

  What you will Get ?

   Best Inflation

   Stocks eBook

        Hot Stocks Alert

     before the opening

                  bell

        Special Offer

      and reports from 

        our partners

100% free. stop anytime no spam

GET YOUR FREE COPY NOW

DOWNLOAD FREE EBOOK

BEST GROWTH STOCKS 2022

We put together a list of the best stocks that we

think can explode over the next 12 months.

2899

SPECIAL GIFT

2900
2901
2902

  What you will Get ?

   Best Growth

   Stocks eBook

        Hot Stocks Alert

     before the opening

                  bell

        Special Offer

      and reports from 

        our partners

2903

100% free. stop anytime no spam

GET YOUR FREE COPY NOW

2915

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

The 5 Best Inflation Stocks for 2022

100% free. stop anytime no spam

Get our free report on the stocks that we recommend for investors who want to protect their portfolios from inflation.

2839

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

The 5 Best Growth Stocks 2022

100% free. stop anytime no spam